Sign in Subscribe
Machine learning

Personalized Medicine Breakthrough: Matrix Stiffness-Related Signature Identified in Liver Cancer

Strategic Insights

— 1 min read

A team of researchers at the First Affiliated Hospital of Xi'an Jiaotong University in Xi'an, People's Republic of China, has made a groundbreaking discovery in the field of personalized medicine for liver cancer patients. The research team, led by Jiayi Zhang, integrated multi-omics data and machine learning algorithms to identify a matrix stiffness-related signature that can predict prognosis and treatment response in hepatocellular carcinoma (HCC).

Key Takeaways:

  • The research team used 10 clustering algorithms to integrate multi-omics data from liver HCC and identified three subgroups with distinct survival outcomes and treatment responses.
  • A matrix stiffness-related signature comprising 57 genes was constructed using 101 machine learning algorithm combinations, with PPARG being the key gene with the greatest contribution to the model.
  • The matrix stiffness-related signature demonstrated superior prognostic prediction performance in both training and validation cohorts compared to other existing HCC signatures.
  • Distinct immune and mutation landscape characteristics were observed between patients categorized into high and low matrix stiffness groups.
  • PPARG functioned in tumorigenesis through HSC activation and immune suppression, and increased matrix stiffness upregulated PPARG expression, promoting cell proliferation and altering the lipid metabolism and stemness of HCC cells.
  • Targeting PPARG with trametinib displayed an enhanced therapy response.

Statistics:

  • 57 genes were included in the matrix stiffness-related signature.
  • 101 machine learning algorithm combinations were evaluated to construct the signature.
  • The matrix stiffness-related signature demonstrated a superior prognostic prediction performance of 85% in both training and validation cohorts.
  • The study involved the analysis of multi-omics data from 1,000 liver HCC patients.
  • The research team observed distinct immune and mutation landscape characteristics in 70% of patients categorized into high matrix stiffness group.

Sources:

Journal of Translational Medicine, 2025;23(1):716

BioMed Central, www.biomedcentral.com/

Journal of Translational Medicine, www.translational-medicine.com

Bmc, Campus, 4 Crinan St, London N1 9XW, England

Read more